Harvard Bioscience, Inc.
HBIO
$7.08
$0.111.58%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -1.06% | -6.42% | -8.06% | -10.60% | -12.24% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -1.06% | -6.42% | -8.06% | -10.60% | -12.24% |
| Cost of Revenue | -3.85% | -9.23% | -6.83% | -6.83% | -8.50% |
| Gross Profit | 1.05% | -4.31% | -8.94% | -13.25% | -14.87% |
| SG&A Expenses | -7.26% | -15.23% | -18.28% | -15.60% | -13.53% |
| Depreciation & Amortization | -31.92% | -27.45% | -23.37% | -17.66% | -9.22% |
| Other Operating Expenses | -- | -- | -79.12% | -79.12% | -79.12% |
| Total Operating Expenses | -6.93% | -12.94% | -14.20% | -13.26% | -12.27% |
| Operating Income | 156.65% | 144.39% | 125.58% | 67.70% | 13.07% |
| Income Before Tax | 81.49% | 82.93% | -391.95% | -301.20% | -503.98% |
| Income Tax Expenses | -128.23% | -251.32% | -192.70% | -72.48% | -63.41% |
| Earnings from Continuing Operations | 81.86% | 83.15% | -357.07% | -278.03% | -437.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 81.86% | 83.15% | -357.07% | -278.03% | -437.61% |
| EBIT | 156.65% | 144.39% | 125.58% | 67.70% | 13.07% |
| EBITDA | 118.89% | 206.33% | 269.32% | 99.83% | 7.37% |
| EPS Basic | 82.17% | 83.35% | -350.45% | -271.87% | -427.30% |
| Normalized Basic EPS | -15.34% | -2.37% | 5.78% | 51.25% | -7.10% |
| EPS Diluted | 81.96% | 83.11% | -348.72% | -270.81% | -421.73% |
| Normalized Diluted EPS | -15.13% | -2.19% | 5.94% | 51.10% | -7.30% |
| Average Basic Shares Outstanding | 1.98% | 1.90% | 1.95% | 1.96% | 1.97% |
| Average Diluted Shares Outstanding | 1.52% | 1.44% | 1.49% | 2.42% | 2.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |